article Open AccessTop 1% cited
Intravenous Immunoglobulin Treatment for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Archives of Dermatology · 2003 · Vol. 139(1) · pp. 33–33
Abstract
The confidence interval of the observed death rate excludes a dramatic decrease in mortality. No measurable effect was observed on the progression of detachment or on the speed of reepidermalization. These results do not support the routine use of IVIG treatment for patients with SJS or TEN, especially in cases of impaired renal function.
Drug-Induced Adverse ReactionsAutoimmune Bullous Skin DiseasesContact Dermatitis and AllergiesToxic epidermal necrolysisMedicineBody surface areaConfidence intervalTotal body surface areaCreatinineRenal functionGastroenterologyAntibodyInternal medicine
MeSH terms
AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesSkinStevens-Johnson SyndromeSurvival RateImmunoglobulins, IntravenousDisease Progression
Citations
381
FWCI
20.95
field-weighted impact
References
16
Percentile
100%
vs. same field & year
Citations per year
References
SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Journal of Investigative Dermatology · 2000 · 1,163 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.